Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Short-term Investments (2016 - 2025)

Tvardi Therapeutics' Short-term Investments history spans 11 years, with the latest figure at $10.1 million for Q4 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a N/A change, with the full-year FY2025 number at $10.1 million, changed N/A from a year prior.
  • Short-term Investments hit $10.1 million in Q4 2025 for Tvardi Therapeutics, down from $15.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for TVRD hit a ceiling of $153.6 million in Q4 2021 and a floor of $408000.0 in Q1 2023.
  • Historically, Short-term Investments has averaged $64.5 million across 5 years, with a median of $42.7 million in 2023.
  • Biggest five-year swings in Short-term Investments: plummeted 99.66% in 2023 and later soared 5482.6% in 2024.
  • Tracing TVRD's Short-term Investments over 5 years: stood at $153.6 million in 2021, then tumbled by 46.83% to $81.7 million in 2022, then plummeted by 40.01% to $49.0 million in 2023, then tumbled by 96.94% to $1.5 million in 2024, then surged by 573.33% to $10.1 million in 2025.
  • Business Quant data shows Short-term Investments for TVRD at $10.1 million in Q4 2025, $15.0 million in Q3 2025, and $20.3 million in Q2 2025.